ProCE Banner Activity

KEYNOTE-028: Pembrolizumab in PD-L1+, ER+/HER2- Breast Cancer

Slideset Download
Conference Coverage
Preliminary data show efficacy and manageable toxicity in 25 patients with PD-L1+, ER+/HER2- advanced breast cancer.

Released: December 15, 2015

Expiration: December 13, 2016

No longer available for credit.

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech BioOncology

Novartis Pharmaceuticals Corporation